Testosterone in males with COVID-19: A 7-month cohort study.
COVID-19
SARS-CoV-2
comorbidities
follow-up
male
testosterone
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
03
08
2021
received:
21
06
2021
accepted:
04
08
2021
pubmed:
20
8
2021
medline:
7
1
2022
entrez:
19
8
2021
Statut:
ppublish
Résumé
Circulating testosterone levels have been found to be reduced in men with severe acute respiratory syndrome coronavirus 2 infection, COVID-19, with lower levels being associated with more severe clinical outcomes. We aimed to assess total testosterone levels and the prevalence of total testosterone still suggesting for hypogonadism at 7-month follow-up in a cohort of 121 men who recovered from laboratory-confirmed COVID-19. Demographic, clinical, and hormonal values were collected for all patients. Hypogonadism was defined as total testosterone ≤9.2 nmol/L. The Charlson Comorbidity Index was used to score health-significant comorbidities. Descriptive statistics and multivariable linear and logistic regression models tested the association between clinical and laboratory variables and total testosterone levels at follow-up assessment. Circulating total testosterone levels increased at 7-month follow-up compared to hospital admittance (p < 0.0001), while luteinizing hormone and 17β-estradiol levels significantly decreased (all p ≤ 0.02). Overall, total testosterone levels increased in 106 (87.6%) patients, but further decreased in 12 (9.9%) patients at follow-up, where a total testosterone level suggestive for hypogonadism was still observed in 66 (55%) patients. Baseline Charlson Comorbidity Index score (OR 0.36; p = 0.03 [0.14, 0.89]) was independently associated with total testosterone levels at 7-month follow-up, after adjusting for age, BMI, and IL-6 at hospital admittance. Although total testosterone levels increased over time after COVID-19, more than 50% of men who recovered from the disease still had circulating testosterone levels suggestive for a condition of hypogonadism at 7-month follow-up. In as many as 10% of cases, testosterone levels even further decreased. Of clinical relevance, the higher the burden of comorbid conditions at presentation, the lower the probability of testosterone levels recovery over time.
Sections du résumé
BACKGROUND
Circulating testosterone levels have been found to be reduced in men with severe acute respiratory syndrome coronavirus 2 infection, COVID-19, with lower levels being associated with more severe clinical outcomes.
OBJECTIVES
We aimed to assess total testosterone levels and the prevalence of total testosterone still suggesting for hypogonadism at 7-month follow-up in a cohort of 121 men who recovered from laboratory-confirmed COVID-19.
MATERIALS AND METHODS
Demographic, clinical, and hormonal values were collected for all patients. Hypogonadism was defined as total testosterone ≤9.2 nmol/L. The Charlson Comorbidity Index was used to score health-significant comorbidities. Descriptive statistics and multivariable linear and logistic regression models tested the association between clinical and laboratory variables and total testosterone levels at follow-up assessment.
RESULTS
Circulating total testosterone levels increased at 7-month follow-up compared to hospital admittance (p < 0.0001), while luteinizing hormone and 17β-estradiol levels significantly decreased (all p ≤ 0.02). Overall, total testosterone levels increased in 106 (87.6%) patients, but further decreased in 12 (9.9%) patients at follow-up, where a total testosterone level suggestive for hypogonadism was still observed in 66 (55%) patients. Baseline Charlson Comorbidity Index score (OR 0.36; p = 0.03 [0.14, 0.89]) was independently associated with total testosterone levels at 7-month follow-up, after adjusting for age, BMI, and IL-6 at hospital admittance.
CONCLUSIONS
Although total testosterone levels increased over time after COVID-19, more than 50% of men who recovered from the disease still had circulating testosterone levels suggestive for a condition of hypogonadism at 7-month follow-up. In as many as 10% of cases, testosterone levels even further decreased. Of clinical relevance, the higher the burden of comorbid conditions at presentation, the lower the probability of testosterone levels recovery over time.
Identifiants
pubmed: 34409772
doi: 10.1111/andr.13097
pmc: PMC8444879
doi:
Substances chimiques
Testosterone
3XMK78S47O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
34-41Subventions
Organisme : Gruppo Prada
Organisme : DiaSorin SpA
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 American Society of Andrology and European Academy of Andrology.
Références
J Med Virol. 2021 Sep;93(9):5295-5309
pubmed: 33990972
Biol Sex Differ. 2020 Sep 18;11(1):53
pubmed: 32948238
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Rev Endocr Metab Disord. 2021 Jun;22(2):275-296
pubmed: 33616801
Andrology. 2021 Jan;9(1):88-98
pubmed: 32436355
Lancet Rheumatol. 2021 Apr;3(4):e253-e261
pubmed: 33655218
Adv Exp Med Biol. 2021;1304:259-321
pubmed: 34019274
F S Rev. 2021 Apr;2(2):140-149
pubmed: 33558864
JAMA Netw Open. 2021 May 3;4(5):e2111398
pubmed: 34032853
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089
pubmed: 32396163
Eur Urol Focus. 2020 Sep 15;6(5):1124-1129
pubmed: 32563676
Cell. 2021 Feb 4;184(3):775-791.e14
pubmed: 33503446
BMC Geriatr. 2021 May 19;21(1):321
pubmed: 34011269
Nat Rev Dis Primers. 2019 May 30;5(1):38
pubmed: 31147553
Open Biol. 2021 Jan;11(1):200347
pubmed: 33465325
Eur Urol. 2021 Sep;80(3):333-357
pubmed: 34183196
Andrology. 2021 Jan;9(1):53-64
pubmed: 32524732
N Engl J Med. 2017 Aug 10;377(6):562-572
pubmed: 28792873
Curr Opin HIV AIDS. 2021 Jan;16(1):48-53
pubmed: 33278160
J Sex Med. 2021 May;18(5):843-848
pubmed: 33903045
Andrology. 2022 Jan;10(1):34-41
pubmed: 34409772
Womens Health (Lond). 2021 Jan-Dec;17:17455065211022262
pubmed: 34096383
Andrology. 2021 Jul;9(4):1043-1052
pubmed: 33635589
Clin Endocrinol (Oxf). 2015 Aug;83(2):268-76
pubmed: 25660119
Crit Care Resusc. 2020 Apr 01;22(2):91-94
pubmed: 32227819
Thorax. 2018 Sep;73(9):840-846
pubmed: 29903755
J Clin Endocrinol Metab. 2010 Jun;95(6):2536-59
pubmed: 20525905
J Sex Med. 2021 Feb;18(2):256-264
pubmed: 33468445
Andrology. 2021 Jan;9(1):99-106
pubmed: 33150723
Ther Adv Endocrinol Metab. 2021 Apr 22;12:20420188211010105
pubmed: 34104394
mBio. 2021 Feb 9;12(1):
pubmed: 33563817
Aging Male. 2020 Dec;23(5):1493-1503
pubmed: 32883151
Andrology. 2021 Jan;9(1):19-22
pubmed: 32369678
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
Redox Biol. 2020 Apr;31:101482
pubmed: 32197947
Eur Urol. 2021 Oct;80(4):523-525
pubmed: 34274135
Andrology. 2021 Jan;9(1):107-114
pubmed: 33152165
Crit Care. 2020 Jun 19;24(1):367
pubmed: 32560707
Clin Exp Rheumatol. 2020 May-Jun;38(3):383-386
pubmed: 32452350